Co-Located Conference AgendasDrug Discovery India 2014 | Drug Metabolism & Discovery ADMET | Indian Lab Automation | Other Track AgendasTrack-1 (Emerald 2): Synthesis & Screening of Drugs & Phytochemicals | Track-2 (Emerald 3): Chemical Biology Approaches to Drug Discovery |
Thursday, 11 September 201408:00 | Registration | 09:15 | Inauguration | 09:20 | Chairman's Welcome and Inaugural Talk | 09:30 | Renaissance in Pharmacognosy: The Need is Great and the Time is Now Rathnam Chaguturu, CEO, Innovation Czar-iDDPartners, United States of America
| 10:15 | Memento Presentation | 10:25 | Coffee and Networking in Exhibition Area | | SESSION 1: Chemical Approaches for Target Identification and Validation |
| | 10:55 | | Keynote Presentation Understanding the Principles for harnessing Key Phosphate Hydrolysis Step in DNA and RNA complexes with Enzymes. Jyoti Chattopadhyaya, Professor, Uppsala University, Sweden
|
| 11:30 | A Novel Approach to Rescue the Neurodegenerative Diseases with the Modified Peptides Derived from Neuron Specific Kinase (Cdk5) Harish Pant, Senior Investigator, National Institute of Health, United States of America
| 12:00 | Chemical Biology Approaches for Target Identification in "Activity Based Proteomic Profiling" Session Maria Costi, Professor, University of Modena and Reggio Emilia, Italy
| 12:30 | Technology Spotlight: Using Protein Design Tools to Guide Pharmacophore Generation and Screening Anand Krishnamurthy, Senior Scientist, Accelrys-BIOVIA
| | SESSION 2: Achieving Therapeutic Goals through PPIs and Epigenetics |
| | 12:45 | | Keynote Presentation Integrative Medicine: A Roadmap of Epigenetic Modulation in Health, Diseases Prevention and Cure Krishna Banaudha, Associate Professor, The George Washington University, United States of America
|
| 13:20 | Rethinking Drug Discovery: Going-in for Signaling Pathways and Novel Chemical Space to Hunt for Next Generation Functional Small Molecules Prabhat Arya, Professor and Head, Dr Reddy's Institute of Life Sciences, India
| 13:50 | Lunch and Networking in Exhibition Area | | SESSION 3: Target based Drug Discovery- New Targets & Novel Approaches |
| | 14:30 | Drugs through Mimicking the Actions of Glycosaminoglycans - Anticoagulants, AntiEmphysema/COPD and Anti-Cancer Stem Cells Umesh Desai, Professor, Virginia Commonwealth University, United States of America
| 15:00 | Technology Spotlight: Maximising Value and Success with Automation Lesley Schultz, Product Manager, Agilent Technologies
| 15:15 | Special Lecture: Protein Ubiquitination Enzymes as Novel Cancer Therapeutic Targets Amit Banerjee, Professor, Wayne State University , United States of America
| 16:15 | Advances in Developing Tankyrase Selective Inhibitors Stefan Krauss, Director, University Of Oslo, Norway
| 16:45 | Molecular Methods that Enable Targeted Therapeutics and Precision Medicine Manohar Furtado, Founder and President, Biology For Global Good Consulting Llc, United States of America
| 17:15 | End of First Day of Conference | 17:30 | FREE WORKSHOP: RNA Silencing for Drug Discovery- Challenges and Strategies |
Friday, 12 September 2014 | SESSION 4: Phenotypic Screening and Cell based Assay Methods for Drug Discovery |
| | 09:30 | Plenary Presentation: Bioprocessing of Human Pluripotent Stem Cells using CompacT SelecT Cell Culture Automation Yacine Laabi, Research Group Leader, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, France
| 10:00 | Stem Cell Based Chip Platforms In Drug Discovery Subadra Dravida, Founder CEO, Tran-Scell Biologics Pvt. Ltd., India
| 10:30 | Technology Spotlight: Fluent Laboratory Automation Solution for Cell based Assays Roland Durner, Global Head of LSB Distributors, Tecan Trading AG
| 10:45 | Coffee Break and Networking in Exhibition Area | 11:05 | Annotating Biological Activities of Drugs, Natural Products and Environmental Toxicants by FACTORIAL Pathway Profiling Assays Sergei Makarov, Chief Executive Officer, Attagene Inc, United States of America
| 11:35 | Cell Based Assays in Clinical Diagnostics: Applications to Neutralizing Antibody Assays, Pharmacogenomics and Personalized Medicine John Watson, Director of Marketing, Promega Corporation, United States of America
| | SESSION 5: Rare Diseases, Orphan Drugs and Drug Repurposing |
| | 12:05 | Optimisation of New Trypanosoma brucei Inhibitors Raphael Rahmani, Research Fellow, Monash University, Australia
| 12:35 | Repositioning of Drugs- Structure-Based Approach Towards Finding New Leads as Antileishmanial Agents Sanjay Batra, Principal Scientist, CSIR Central Drug Research Institute, India
| 13:05 | Special Lecture: Natural Products Repurposing for Cancer Therapy Petr Bartunek, Group Leader, Institute of Molecular Genetics, Czech Republic
| 13:40 | Lunch and Networking in Exhibition Area | 14:20 | POSTER EVALUATION | | SESSION 6: Collaborative and Open Source Drug Discovery |
| | 14:40 | Accelerated and Reliable Lead Discovery: Structure Guided Drug Discovery Ideal for Collaborative Projects Kal Ramnarayan, President and Chief Scientific Officer, Sapient Discovery, United States of America
| 15:10 | Opportunities for Strategic Research Partnerships in Drug Discovery Ajith Kamath, Head, Pfizer Inc, India
| 15:40 | Crowdsourcing Systems Level Platform for Open Source Drug Discovery Anshu Bhardwaj, Scientist, CSIR- Open Drug Discovery Unit, India
| 16:00 | Open Source Drug Discovery for Tuberculosis: Lessons to learn Anamik Shah, Vice Chancellor, Gujarat Vidyapith, India
| 16:20 | Open Discussion on Open Source Drug Discovery | 16:40 | Coffee Break and Networking in Exhibition Area | 16:55 | Panel Discussion: Drug Discovery- Contract Research Landscape in India 2020 | 17:30 | End of the Conference |
|